Literature DB >> 8778163

Inositolphosphoglycans are possible mediators of the glucagon-like peptide 1 (7-36)amide action in the liver.

M A Trapote1, F Clemente, C Galera, M Morales, A I Alcántara, M I López-Delgado, M L Villanueva-Peñacarrillo, I Valverde.   

Abstract

A potent glycogenic effect for GLP-1(7-36)amide has been found in rat hepatocytes and skeletal muscle, and the specific receptors detected for GLP-1(7-36)amide in these tissue membranes do not seem to be associated to adenylate cyclase. On the other hand, inositolphosphoglycan molecules (IPGs) have been implicated as second messengers in the action of insulin. In a human hepatoma cell line (HEP G-2), we have observed the presence of [125I]GLP-1(7-36)amide specific binding, and a stimulatory effect of the peptide upon glycogen synthesis, confirming the findings in isolated rat hepatocytes. Also, GLP-1(7-36)amide modulates the cell content of radiolabelled glycosylphosphatidylinositols (GPIs), in the same manner as insulin, indicating hydrolysis of GPIs and an immediate and short-lived generation of IPGs. Thus, IPGs could be mediators in the GLP-1(7-36)amide glycogenic action in the liver.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8778163     DOI: 10.1007/BF03349846

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  28 in total

1.  Partial structure of an insulin-sensitive glycophospholipid.

Authors:  J M Mato; K L Kelly; A Abler; L Jarett; B E Corkey; J A Cashel; D Zopf
Journal:  Biochem Biophys Res Commun       Date:  1987-07-31       Impact factor: 3.575

2.  Insulin stimulates the generation from hepatic plasma membranes of modulators derived from an inositol glycolipid.

Authors:  A R Saltiel; P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

3.  Extracellular calcium modulates insulin's action on enzymes controlling cyclic AMP metabolism in intact hepatocytes.

Authors:  F Irvine; A V Wallace; S R Sarawak; M D Houslay
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

4.  Metabolic labelling and partial characterization of glycophospholipids in pancreatic islet cells.

Authors:  A Albor; J Cámara; J M Mato; W J Malaisse; I Valverde
Journal:  Cell Biochem Funct       Date:  1991-04       Impact factor: 3.685

5.  Identification of a novel insulin-sensitive glycophospholipid from H35 hepatoma cells.

Authors:  J M Mato; K L Kelly; A Abler; L Jarett
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

6.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Authors:  B Thorens
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

7.  Impairment of glycosyl-phosphatidylinositol-dependent insulin signaling system in isolated rat hepatocytes by streptozotocin-induced diabetes.

Authors:  J A Sanchez-Arias; J C Sanchez-Gutierrez; A Guadaño; J F Alvarez; B Samper; J M Mato; J E Feliu
Journal:  Endocrinology       Date:  1992-10       Impact factor: 4.736

8.  Insulin provokes co-ordinated increases in the synthesis of phosphatidylinositol, phosphatidylinositol phosphates and the phosphatidylinositol-glycan in BC3H-1 myocytes.

Authors:  R V Farese; D R Cooper; T S Konda; G Nair; M L Standaert; R J Pollet
Journal:  Biochem J       Date:  1988-11-15       Impact factor: 3.857

9.  Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphate contains galactosamine and D-chiroinositol.

Authors:  J Larner; L C Huang; C F Schwartz; A S Oswald; T Y Shen; M Kinter; G Z Tang; K Zeller
Journal:  Biochem Biophys Res Commun       Date:  1988-03-30       Impact factor: 3.575

10.  Glucagon-like peptide-1 binding to rat skeletal muscle.

Authors:  E Delgado; M A Luque; A Alcántara; M A Trapote; F Clemente; C Galera; I Valverde; M L Villanueva-Peñacarrillo
Journal:  Peptides       Date:  1995       Impact factor: 3.750

View more
  6 in total

Review 1.  Glucagon-like peptide 1 (GLP-1) and metabolic diseases.

Authors:  C M Rotella; L Pala; E Mannucci
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

2.  Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models.

Authors:  M L Villanueva-Peñacarrillo; J Puente; A Redondo; F Clemente; I Valverde
Journal:  Endocrine       Date:  2001-07       Impact factor: 3.633

3.  Cytokine production by CAPAN-1 and CAPAN-2 cell lines.

Authors:  J A Blanchard; S Barve; S Joshi-Barve; R Talwalker; L K Gates
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

4.  Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors.

Authors:  Dominique Dardevet; Mary Courtney Moore; Catherine A DiCostanzo; Ben Farmer; Doss W Neal; Wanda Snead; Margaret Lautz; Alan D Cherrington
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-07-28       Impact factor: 4.052

Review 5.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

6.  Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats.

Authors:  Elisabeth L Raab; Patricia M Vuguin; Doris A Stoffers; Rebecca A Simmons
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-10-21       Impact factor: 3.619

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.